ARTICLE | Clinical News
Icos-Texas Biotech start pivotal trial
May 30, 2001 7:00 AM UTC
Icos-Texas Biotechnology, a joint venture between Icos (ICOS) and Texas Biotech (TXB) started a North American Phase II/III trial of its sitaxsentan once daily oral endothelin-A receptor antagonist in...